CNS Tumor

P1, N=40, Active, not recruiting, Iovance Biotherapeutics, Inc. | Recruiting --> Active, not recruiting

Conclusions Due to their rarity, these tumors may be overlooked in clinical practice. The low availability of diagnostic tests in many centers may contribute to the underestimation of the incidence of SFTs.

The patient remained in complete remission 40 months after the completion of chemoradiotherapy and 51 months after the initial surgery. This case demonstrates that stereotactic radiotherapy combined with doxorubicin-ifosfamide chemotherapy can achieve durable tumor control in PIS-DICER1, suggesting a potential therapeutic option for this highly aggressive tumor.

Importantly, co-targeting these pathways was able to overcome resistance to TEADi and was superior to MEK/mTOR/FAK inhibition alone. These studies provide a compelling proof-of-concept that TEADi represents a novel therapeutic vulnerability in meningioma and reveal adaptive signaling responses that can be therapeutically exploited.

P=N/A, N=1800, Recruiting, Mayo Clinic | Trial completion date: Oct 2026 --> Oct 2028 | Trial primary completion date: Oct 2026 --> Oct 2028

IT trastuzumab in combination with GM-CSF is safe in recurrent pediatric PF EPN. A larger phase 2 study that includes both recurrent PFA and RELA-ST EPN is needed to determine the long-term efficacy of this immunotherapy strategy.

P=N/A, N=33, Completed, Mayo Clinic | Recruiting --> Completed | N=80 --> 33 | Trial completion date: Apr 2026 --> Jan 2026 | Trial primary completion date: Apr 2026 --> Jan 2026

MASLD and visceral adiposity are highly prevalent in craniopharyngioma survivors, driven by hypothalamic-pituitary dysfunction. Routine metabolic and hepatic screening, beyond BMI, and optimized endocrine care are vital to prevent long-term morbidity in this vulnerable population.

While challenges such as data scarcity and the "black box" nature of algorithms persist, innovative strategies offer potential solutions to AI application. AI serves as a transformative tool for personalized precision management, potentially bridging diagnostic disparities and optimizing clinical outcomes for children with central nervous system tumors.

Our study highlights the importance of understanding tumor-specific factors that limit CAR T-cell response and using this information to design superior next-generation CAR T-cells. Specifically, we identify cytoskeleton remodeling and T cell motility as therapeutically actionable targets for future engineering approaches.